Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Clinical trial NCT04542369 · UNKNOWN
Trial details
- NCT number
- NCT04542369
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-01
- Primary completion
- 2023-12-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.